New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
06:38 EDTWCRX, ENDP, COV, VRX, TEVAFidelity Investments wants an Endo Health Solution's sale, Bloomberg reports
Fidelity Investments, Endo Health Solutions's (ENDP) largest shareholder, wants a sale, sources say, reports Bloomberg. It may be the company's best hope at regaining investor confidence after losing more than $1B in market value, or to undo the acquisitions that built the company. Endo has the lowest valuation in the U.S. specialty pharmaceuticals industry, according to Bloomberg data. On average, analysts see Endo getting at least a 26% premium in a deal. Teva Pharmaceutical Industries (TEVA) or Covidien Plc (COV) could go after parts or all of Endo, according to Stifel Financial Corp. Gabelli & Co. said Endo could break up or sell its pain drugs to Warner Chilcott Plc (WCRX) or Valeant Pharmaceuticals International (VRX). Reference Link
News For ENDP;TEVA;COV;WCRX;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
06:31 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Subscribe for More Information
May 15, 2015
17:40 EDTENDPEndo announces FDA approval of label update for XIAFLEX
Subscribe for More Information
17:15 EDTVRXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTTEVA, ENDP, VRXSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTVRXPershing Square gives quarterly update on stakes
Subscribe for More Information
10:55 EDTVRXJANA Partners gives quarterly update on stakes
Subscribe for More Information
09:31 EDTTEVAAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:12 EDTTEVATeva migraine treatment data positive, says Bernstein
Subscribe for More Information
08:04 EDTTEVATeva to present new respiratory data at 2015 ATS conference
Teva Pharmaceutical Industries announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society International Conference in Denver, Colorado on May 15-19.Data to be presented include a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir RespiClick inhalation powder, which gained approval from the U.S. FDA in March 2015. ProAir RespiClick is now available by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. Additional Phase III data to be presented include a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented includes data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler in adolescent and adult patients with asthma.
May 14, 2015
19:02 EDTENDPOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTENDPEndo, BioDelivery announces Phase 3 data for buprenorphine
Subscribe for More Information
08:35 EDTTEVATeva says data present case for TEV-48125 progression to Phase III
Subscribe for More Information
07:44 EDTTEVAInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
May 13, 2015
08:02 EDTTEVAANI Pharmaceuticals acquires rights to testosterone gel 1%
Subscribe for More Information
May 11, 2015
14:27 EDTTEVACowen recommends adding to both Teva and Mylan at current levels
Cowen recommends adding to both Teva (TEVA) and Mylan (MYL) at current levels. The firm continues to believe that a Mylan transaction will proceed despite some early contentious language, and all of Mylan's concerns will be resolved.
11:53 EDTTEVATeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information
07:34 EDTENDPEndo acquires portfolio of branded and generic products from Aspen Holdings
Subscribe for More Information
07:13 EDTENDPEndo raises FY15 adjusted EPS to $4.40-$4.60 from $4.35-$4.55, consensus $4.48
Sees FY15 revenue $2.9B-$3B, consensus $2.99B. Sees FY15 adjusted gross margin of between 64%-65%. Sees FY15 effective tax rate of 13%-14%.
07:12 EDTENDPEndo reports Q1 US Branded Pharmaceuticals revenue $285M
Reports Q1 US Generic Pharmaceuticals revenue $357M. Reports Q1 International Pharmaceuticals revenue $73M.
07:11 EDTENDPEndo reports Q1 adjusted EPS $1.17, consensus $1.06
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use